emapalumab

Home
Ligands
emapalumab

GtoPdb Ligand ID: 9295

Synonyms: emapalumab-lzsg | Gamifant® | NI-0501 | NI0501

emapalumab is an approved drug (FDA (2018))

Comment: Emapalumab (NI-0501) is a fully human monoclonal antibody that targets interferon gamma (IFNγ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2006109191, and in which NI-0501 is confirmed as an exemplary antibody [2].

Summary
Biological activity
Clinical data
References
Immunopharmacology

Immunopharmacology Comments
Emapalumab is an anti-IFNγ therapy. It is the first drug specifically targeted for the treatment of primary HLH, and represents a major advance in treatment for this ultra-rare syndrome.

Immunopharmacology Comments

Emapalumab is an anti-IFNγ therapy. It is the first drug specifically targeted for the treatment of primary HLH, and represents a major advance in treatment for this ultra-rare syndrome.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Hemophagocytic lymphohistiocytosis	Disease Ontology: DOID:0050120 OMIM: 603552 Orphanet: ORPHA158032	Approved therapy for HLH in adult and pediatric patients (FDA 2018).	1